According to the most recent Global Use of Medicine report issued by the IQVIA Institute for Human Data Science, losses for originator products are projected to rise by over $80 billion over the next 5 years due to market introductions of new biosimilar and generic drugs.
Although vaccination proves effective against severe infections, its impact on respiratory function in mild cases remains uncertain, particularly among health care workers.
Speakers at AMCP Nexus 2023 provided an in-depth understanding of how changes brought on by the Inflation Reduction Act (IRA) have impacted Medicare, as well as what provisions are to come.
Attendees at an AMCP Nexus 2023 session received an overview of FDA approvals granted in 2023 as well as a preview of nononcology drugs to be released over the next 5 years.
Panelists at AMCP Nexus 2023 provided a rundown of the 340B discount program and addressed whether it's actually working to lower out-of-pocket costs for patients.
Providers create a disparity themselves by choosing not to treat obesity because stigma has led them to believe that patients with obesity are not sick enough to warrant medical intervention.
The risk of drug shortages is increasing as the long-term sustainability of generic manufacturing faces challenges, including low return on investment because of lowered prices, drug purchasers becoming more concentrated, and new generics facing slow adoption.
Yusimry (adalimumab-aqvh) is 1 of 9 FDA-approved adalimumab biosimilars and is a low-concentration, citrate-free product.
Parcel tracking technology that used predictive analytics can help with real-time package delivery monitoring and ensure on-time delivery.
Discussions around women’s health should extend beyond talking about menstruation and pregnancy to include all aspects of health.
Juliana Reed, executive director of the Biosimilars Forum, discussed the impact of market dynamics and changing pricing structures during a presentation at the 2023 Asembia Specialty Pharmacy Summit.
Although there’s a greater trend toward digital communication and monitoring tools, patient trust needs to extend beyond the health care system and their providers.
88% of surveyed payers said interchangeability will have the biggest impact on adoption.
The Inflation Reduction Act boosted the Medicare payment for biosimilars from the standard average sales price plus 6% to 8%.
At the 2023 Asembia Specialty Pharmacy Summit, panelists discussed how inflation rebates and a redesign of Medicare Part D plans will impact payers and manufacturers.
November 2nd 2023
